Details

Role of human plasma metabolites in prediabetes and type 2 diabetes from the IMI-DIRECT study
ID Sharma, Sapna (Author), ID Adamski, Jerzy (Author), ID Grallert, Harald (Author), et al.

.pdfPDF - Presentation file, Download (1,76 MB)
MD5: CA6A998B5302C9848DEBCA9A5A929A20
URLURL - Source URL, Visit https://link.springer.com/article/10.1007/s00125-024-06282-6 This link opens in a new window

Abstract
Aims/hypothesis: Type 2 diabetes is a chronic condition that is caused by hyperglycaemia. Our aim was to characterise the metabolomics to find their association with the glycaemic spectrum and find a causal relationship between metabolites and type 2 diabetes. Methods: As part of the Innovative Medicines Initiative - Diabetes Research on Patient Stratification (IMI-DIRECT) consortium, 3000 plasma samples were measured with the Biocrates AbsoluteIDQ p150 Kit and Metabolon analytics. A total of 911 metabolites (132 targeted metabolomics, 779 untargeted metabolomics) passed the quality control. Multivariable linear and logistic regression analysis estimates were calculated from the concentration/peak areas of each metabolite as an explanatory variable and the glycaemic status as a dependent variable. This analysis was adjusted for age, sex, BMI, study centre in the basic model, and additionally for alcohol, smoking, BP, fasting HDL-cholesterol and fasting triacylglycerol in the full model. Statistical significance was Bonferroni corrected throughout. Beyond associations, we investigated the mediation effect and causal effects for which causal mediation test and two-sample Mendelian randomisation (2SMR) methods were used, respectively. Results: In the targeted metabolomics, we observed four (15), 34 (99) and 50 (108) metabolites (number of metabolites observed in untargeted metabolomics appear in parentheses) that were significantly different when comparing normal glucose regulation vs impaired glucose regulation/prediabetes, normal glucose regulation vs type 2 diabetes, and impaired glucose regulation vs type 2 diabetes, respectively. Significant metabolites were mainly branched-chain amino acids (BCAAs), with some derivatised BCAAs, lipids, xenobiotics and a few unknowns. Metabolites such as lysophosphatidylcholine a C17:0, sum of hexoses, amino acids from BCAA metabolism (including leucine, isoleucine, valine, N-lactoylvaline, N-lactoylleucine and formiminoglutamate) and lactate, as well as an unknown metabolite (X-24295), were associated with HbA1c progression rate and were significant mediators of type 2 diabetes from baseline to 18 and 48 months of follow-up. 2SMR was used to estimate the causal effect of an exposure on an outcome using summary statistics from UK Biobank genome-wide association studies. We found that type 2 diabetes had a causal effect on the levels of three metabolites (hexose, glutamate and caproate [fatty acid (FA) 6:0]), whereas lipids such as specific phosphatidylcholines (PCs) (namely PC aa C36:2, PC aa C36:5, PC ae C36:3 and PC ae C34:3) as well as the two n-3 fatty acids stearidonate (18:4n3) and docosapentaenoate (22:5n3) potentially had a causal role in the development of type 2 diabetes. Conclusions/interpretation: Our findings identify known BCAAs and lipids, along with novel N-lactoyl-amino acid metabolites, significantly associated with prediabetes and diabetes, that mediate the effect of diabetes from baseline to follow-up (18 and 48 months). Causal inference using genetic variants shows the role of lipid metabolism and n-3 fatty acids as being causal for metabolite-to-type 2 diabetes whereas the sum of hexoses is causal for type 2 diabetes-to-metabolite. Identified metabolite markers are useful for stratifying individuals based on their risk progression and should enable targeted interventions.

Language:English
Keywords:N-lactoyl-amino acid metabolites, glycaemic traits, metabolomics, type 2 diabetes
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:Str. 2804-2818
Numbering:Vol. 67, iss. 12
PID:20.500.12556/RUL-182318 This link opens in a new window
UDC:577:61
ISSN on article:1432-0428
DOI:10.1007/s00125-024-06282-6 This link opens in a new window
COBISS.SI-ID:265238019 This link opens in a new window
Publication date in RUL:07.05.2026
Views:231
Downloads:133
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Diabetologia
Shortened title:Diabetologia
Publisher:Springer Nature
ISSN:1432-0428
COBISS.SI-ID:512012825 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:N-laktoilaminokisline, glikemične lastnosti, metabolomika, sladkorna bolezen tipa 2

Projects

Funder:EC - European Commission
Funding programme:Innovative Medicines Initiative Joint Undertaking
Project number:115317
Acronym:DIRECT

Funder:European Federation of Pharmaceutical Industries and Associations

Funder:DZD - Helmholtz Munich, German Diabetes Center

Funder:CRC - China Research Council

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back